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Background. Recent data suggest that chronic hepatitis C has to be considered a metabolic disease further to a viral infection. The
aim of this study was to elaborate on the complex interactions between hepatitis C virus, host metabolic factors, and treatment
response. Methods. Demographic, virological, and histological data from 356 consecutive patients were analyzed retrospectively.
Hepatic steatosis, obesity, and insulin resistance were examined in relation to their impact on treatment outcome. Comparison
between genotype 1 and 3 patients was performed to identify diﬀerences in the determinants of hepatic steatosis. Results.
Histological evidence of hepatic steatosis was found in 113 patients, distributed in 20.3%, 9.0%, and 2.5% for grades I, II, and
III, respectively. Hepatic steatosis was associated with past alcohol abuse (P = 0.003) and histological evidence of advanced ﬁbrosis
(P<0.001). Older age (OR 2.51, P = 0.002), genotype (OR 3.28, P<0.001), cirrhosis (OR 4.23, P = 0.005), and hepatic
steatosis (OR 2.48, P = 0.001) were independent predictors for nonresponse. Correlations of hepatic steatosis with alcohol, insulin
resistance, and ﬁbrosis stage were found similar for both genotypes 1 and 3. Conclusions. Host metabolic factors may predict
treatment outcome, and this impact remains signiﬁcant even in genotype 3, where steatosis has been believed to be exclusively
virus related.
1.Introduction
Current treatment of chronic hepatitis C (CHC) consists of
pegylated interferon alpha (PegIFNα) plus ribavirin with an
overall sustained virological response (SVR) of 54–63% [1–
3]. Even with high adherence to treatment duration, SVR
rates remain suboptimal, and several host and viral factors,
like age, gender, ethnicity, genotype, and stage of hepatic
ﬁbrosis, have been identiﬁed as inﬂuencing the rate of CHC
progression as well as the response to antiviral therapy [4–6].
Hepatic steatosis is a common histological feature of
CHC, occurring in approximately 50% [7], twice as often
as would be expected in the general population by simple
coexistence of nonalcoholic fatty liver disease (NAFLD) and
CHC [8, 9]. Even after exclusion of the usual causes of
steatosis, such as obesity, diabetes, alcohol, and drugs, the
prevalence of steatosis is still around 30–40% [10, 11]. The
majority of cases account for mild steatosis, aﬀecting less
than 30% of hepatocytes [7].
The pathogenesis of hepatic steatosis in the setting of
CHC has been reported to be dual [7, 12, 13]; in the so-
called “metabolic” steatosis, fat accumulation in the liver
is the result of host metabolic factors like obesity, alcohol
consumption, and diabetes, in a way that resembles the
derangement of hepatocytes’ lipid metabolism in NAFLD
[11,14,15].Ontheotherhand,hepatitisCvirus(HCV)itself2 Gastroenterology Research and Practice
has a direct steatogenic eﬀect [12, 16, 17], as viral structural
andnonstructuralproteinslocalizeonlipiddroplets,interact
with apolipoproteins, and interfere with molecular pathways
of lipid metabolism [18]. In the setting of this viral-induced
steatosis, several reports have demonstrated that exclusively
HCV genotype 3 is cytopathic to the liver leading to a
more prevalent and a more severe in extent steatosis. In
this case, hepatic steatosis has been found to correlate
with HCV RNA and to improve after viral clearance [19].
However, several issues concerning this genotype-speciﬁc
steatosis remain to be elucidated, as experimental models
of transgenic mice have used constructs derived from HCV
genotype 1 isolates [7, 19, 20], and genomic studies have
failed so far to explain the greater propensity of genotype
3 to cause steatosis [21]. Furthermore, several authors have
suggested that, as host and viral interactions are far more
complex than previously described, more “mixed” types of
steatosis would be recognized in the future, especially as
obesity tends to aﬀect younger generations [5, 13].
Apart from hepatic steatosis [6, 22–25], researchers have
focused on other metabolic factors like obesity [26, 27]
and, more recently, insulin resistance (IR) [28–30]. Proposed
mechanisms for decreased eﬀectiveness of antiviral therapy
include enhanced ﬁbrosis secondary to hepatic steatosis and
IR, altered immune responses, and distortion of hepatocyte
binding for interferon secondary to hepatic fat deposition
[14].
Theaimofthepresentstudyistoprovideaclearerunder-
standing about the interaction between hepatic steatosis,
obesity, IR, and current antiviral therapy. Furthermore, this
study examines possible virus-related diﬀerences concerning
the impact of the metabolic proﬁle of the host on treatment
outcome.
2. Patientsand Methods
2.1. Patient Selection. Databases from ﬁve major hepatology
units were used to select data from CHC patients who
had been subjected to pretreatment liver biopsy. These
databases provided demographic, serological, virological,
andhistologicaldatafromatotalof 795consecutivepatients.
Patients, who neither received nor completed therapy, were
excluded from the study. According to inclusion criteria,
patients had to be na¨ ıve, aged above 18 years, and have
received therapy for more than 80% of the recommended
treatment duration. Figure 1 demonstrates patients entering
the study, as well as distribution of genotypes, and type of
antiviral therapy.
2.2. Demographic Data. Databases were used to determine
patients’ age, gender, history of alcohol consumption, and
somatometric measurements. Previous intravenous drug
use (IVDU) was also recorded as a possible mode of
HCV transmission. Past alcohol abuse was deﬁned as a
consumption of more than 120g alcohol per week, at least
6 months prior to the beginning of treatment. Weight and
heightmeasurementswereused tocalculatebody massindex
(BMI).
2.3. Laboratory Investigations. Baseline serum alanine (ALT)
and aspartate aminotransferases (AST) were measured by
standard biochemical analysers. Abnormal values were con-
sidered as values just above the upper limit of normal.
In a subgroup of CHC patients, an overnight fasting
blood sample was taken in advance of therapy onset for
further assessment of IR using the homeostasis model assess-
ment (HOMA), as well as measurement of total cholesterol,
serum triglyceride concentration, fasting glucose, insulin,
and C-peptide. Patients with HOMA ≥ 2 were considered to
be insulin resistant [28].
2.4. Virology Assessments. All patients were HCV-RNA
positive by qualitative polymerase chain reaction (PCR).
HCV RNA was determined by reverse transcriptase PCR
using commercial kits (Amplicor HCV, Roche Diagnostics,
Branchburg, NJ). HCV genotyping was performed with a
second-generation reverse hybridization line probe assay
(INNO-LiPA HCV II, Belgium). Baseline high viral load was
deﬁned as HCV RNA greater than 800,000IU/mL.
2.5. Liver Histology. Inﬂammatory activity and ﬁbrosis were
assessed according to the METAVIR scoring system [31]
(4 stages for activity: A0–A3 and 5 stages for ﬁbrosis: F0–
F4) or the modiﬁed Ishak score [32] (Histology Activity
Index (HAI) scale 0–18 and ﬁbrosis scale 0–6). Severe
inﬂammation was considered as having either A3 or HAI >
12. Advanced ﬁbrosis was deﬁned as stage ≥F3 or ≥4, while
cirrhosis was deﬁned as having stage F4 or stages ≥5, for the
two scoring systems, respectively.
Steatosis was semiquantiﬁed by determining the propor-
tion of hepatocytes containing fat droplets. According to
Brunt’s classiﬁcation [33], specimens were assigned a grade
(0 to III) based upon the percentage of aﬀected hepatocytes.
Grade 0 was considered as absence of hepatic steatosis.
2.6. Treatment Outcomes. All patients included in the study
were treated with combination therapy of either PegINFα-
2a (180μg/w) or PegIFNα-2b (1.5μg/kg/w), combined with
ribavirin, according to guidelines [34], as shown in Figure 1.
Adherence to standard dosage was deﬁned as positive
when patients constantly received more than 80% of the
recommended dosage. Primary endpoint of the study was
SVR, deﬁned as undetectable HCV RNA 24 weeks after the
e n do ft r e a t m e n t .
2.7. Statistical Analysis. Treatment outcome was analyzed as
the dependent dichotomous categorical variable. Statistical
tests of chi-square, Student’s t-test or Mann-Whitney, were
used as appropriate for group comparisons. Finally, a
multiple logistic regression analysis model was applied in
order to determine possible independent prognostic factors
of SVR. All statistical analyses were made using SPSS v11.5.
P values were considered statistically signiﬁcant at the 0.05
level.Gastroenterology Research and Practice 3
Total database entries
795 HCV patients
362 patients not treated
or discontinued
433 patients
completed therapy
77 patients met
exclusion criteria
Total 356 patients
included
genotype 1 genotype 4 not deﬁned genotype 2 genotype 3
48 weeks
plus
weight-based ribavirin
24 weeks
plus
ribavirin 800 mg/d
164 (46.1%) 45 (12.6%) 11 (3.1%) 23 (6.5%) 113 (31.7%)
PegIFNα PegIFNα
Figure 1: Patients entering the study.
3. Results
3.1. Baseline Host and Viral Characteristics. A total of 356
consecutive CHC patients were included in the study. Patient
baseline characteristics were 197 (55.3%) male, 203 (57.8%)
aged above 40, 111 (31.3%) former IVDUs, 41 (12%) past
alcohol abusers, and 49 (36.6%) overweight with mean BMI
23.3 ± 4.0kg/m 2. The majority of HCV patients (96.2% and
77.2%) had abnormal baseline ALT and AST, respectively,
while approximately half of them (n = 67, 42.7%) presented
with high viral load. Liver histology found 56 patients
(15.9%) with advanced ﬁbrosis, 21 (6%) with cirrhotics,
17 (5.1%) with severe necroinﬂammatory activity, and 113
(31.7%) with evidence of hepatic steatosis. Demographic,
virological, and histological data according to the genotype
are shown in Table 1.
3.2. Treatment Outcome. A total of 251 (70.5%) patients
achieved SVR, while the remaining 105 patients did not
respond or had a viral relapse. SVR rates were 67.7%, 73.9%,
86.7%, and 40.0% for genotypes 1, 2, 3, and 4, respectively.
Variables with strong correlation to treatment outcome
were selected for statistical analysis with the multiple logistic
regression method (Table 2). IVDU was strongly correlated
with genotype 3 (χ2, P ≤ 0,001) and, thus, was excluded
from the model. Four categorical variables with strong
correlation to treatment outcome were selected for the
multiple logistic regression analysis: presence of cirrhosis,
g e n o t y p e1o r4c o m p a r e dt og e n o t y p e s2o r3 ,a g ea b o v e
40 years, and hepatic steatosis. The results of the multiple
logistic regression analysis including the odd ratios and
95% conﬁdence intervals (CI) are shown in Table 3.M o d e l
validity was tested with the Hosmer-Lemeshow’s goodness-
o f - ﬁ tt e s t( P = 0.969 >0.05).
3.3. Impact of Hepatic Steatosis on Treatment Outcome. A
total of 241 patients (67.7%) had no steatosis in liver biopsy,
while 72 (20.2%), 32 (9.0%), and 9 (2.5%) patients had
histological evidence of grade I, II, and III hepatic steatosis,
respectively.
Presence of hepatic steatosis was found to be associated
with past alcohol abuse (P = 0.003), high viral load4 Gastroenterology Research and Practice
Table 1: Demographic, virological, and histological data according to genotype.
Genotype 1
n = 164
Genotype 2
n = 23
Genotype 3
n = 113
Genotype 4
n = 46 P values∗
Gender (males%) 87 (53.0) 12 (52.2) 66 (58.4) 24 (53.3) 0.826
Age ≥ 40 years (n%) 110 (67.5) 19 (82.6) 41 (36.9) 30 (68.2) <0.001
IVDU (n%) 40 (24.4) 3 (13.0) 59 (52.7) 6 (13.3) <0.001
Alcohol abuse (n%) 15 (9.3) 2 (8.7) 17 (15.7) 6 (14.0) 0.392
BMI (kg/m2)2 3 .6 ±4.82 6 .4 ±3.92 3 .2 ±3.42 3 .5 ± 4.1 0.144
Overweight (n%) 15 (32.6) 7 (70.0) 18 (32.1) 8 (40.0) 0.126
High viral load (n%) 23 (33.3) 3 (37.5) 32 (55.2) 9 (42.9) 0.101
Hepatic steatosis (n%) 46 (28.2) 8 (34.8) 37 (32.7) 16 (35.6) 0.721
Severe inﬂammation (n%) 10 (6.5) 0 (0) 3 (2.9) 2 (4.7) 0.406
Advanced ﬁbrosis (n%) 23 (14.1) 4 (17.4) 17 (15.3) 11 (24.4) 0.411
Cirrhosis (n%) 7 (4.3) 1 (4.3) 8 (7.2) 5 (11.1) 0.356
∗Comparison between genotypes with χ2 (nonparametrical) or one-way ANOVA (parametrical variables).
Table 2: Variable associations with SVR.
SVR
(n = 251)
Response failure
(n = 105) P values
Gender (males%) 145 (57.8) 52 (49.5) 0.154
Age ≥ 40 years (n%) 123 (49.60) 80 (77.7) <0.001
IVDU (n%) 95 (37.8) 16 (15.4) <0.001
Alcohol abuse (n%) 27 (11.2) 14 (14.1) 0.442
BMI (kg/m2)2 3 .1 ±3.82 4 .6 ±4.5 0.035
Overweight (n%) 24 (28.6) 25 (50.0) 0.013
Genotype distribution <0.001
Genotype 1 111 (45.5) 53 (52.5)
Genotype 2 17 (7.0) 6 (5.9)
Genotype 3 98 (40.2) 15 (14.9)
Genotype 4 18 (7.4) 27 (26.7)
High viral load (n%) 39 (40.6) 28 (45.8) 0.515
Abnormal ALT (n%) 236 (96.7) 95 (95.0) 0.447
Abnormal AST (n%) 199 (86.1) 77 (86.5) 0.931
Hepatic steatosis (n%) 64 (25.7) 49 (46.7) <0.001
Severe inﬂammation (n%) 9 (3.8) 8 (8.5) 0.080
Advanced ﬁbrosis (n%) 26 (10,5) 30 (28,6) <0.001
Cirrhosis (n%) 7 (2,8) 14 (13,3) <0.001
Type of IFN 0.987
PegIFNα-2a (n%) 69 (28.6) 27 (28.7)
PegIFNα-2b (n%) 172 (71.4) 67 (71.3)
Dosage adherence (n%) 173 (80.8) 60 (82.2) 0.799
Table 3: Multiple logistic regression analysis for nonresponse.
Variables B SE Wald df P values OR 95% CI
Lower Upper
Age ≥ 40 years 0.92 0.30 9.68 1 0.002 2.5 1.41 4.47
Genotype 1or 4 1.19 0.31 15.05 1 0.0001 3.28 1.80 5.60
Hepatic steatosis 0.91 0.28 10.84 1 0.001 2.48 1.44 4.26
Cirrhosis 1.44 0.52 7.80 1 0.005 4.23 1.54 11.64
Constant −2.70 0.34 63.15 1 0.0001 0.067Gastroenterology Research and Practice 5
(P = 0.008), abnormal ALT and AST (P = 0.015 and P =
0.026 resp.), severe necro-inﬂammatory activity (P<0.001),
and advanced ﬁbrosis (P<0.001). As shown in Table 4,
genotype distribution did not diﬀer between two groups.
However, the majority of patients with grade III hepatic
steatosis in liver biopsy (6 out of 9, 66.6%) were patients
infected with HCV genotype 3 (data not shown).
SVR was achieved in 185 patients without hepatic
steatosis (76.8%) versus 64 patients (56.6%) with steatosis
≥33% in pretreatment liver biopsy (P<0.001). As already
mentioned, presence of hepatic steatosis was found to be
a strong predictor for non-response, independently of age,
genotype, and ﬁbrosis stage.
3.4. Impact of BMI on Treatment Outcome. Data about BMI
measurements were available only for 134 patients (37.6% of
total).BMIrangedbetween14.4and34.1kg/m2,withamean
value 23.7 ± 4.1kg/m 2. The majority of patients (63.4%)
had a BMI within normal, while 29.1% were overweight and
7.5% were obese.
BMI was found to be higher in nonresponders (24.6±4.5
versus 23.1 ± 3.8kg/m 2,S t u d e n t ’ st-test, P = 0.035), in
older patients (P = 0.028), and in males (P = 0.024)
but not in former alcoholics (P = 0.059) or cirrhotics
(P = 0.09). No statistical signiﬁcant associations were found
regarding hepatic steatosis. However, taking into account the
strongassociationofsteatosiswithalcoholandﬁbrosis,when
alcohol abusers and cirrhotics were excluded, the percentage
of overweight patients increased in higher grades of hepatic
steatosis (27.8%, 30.3%, 35.7%, and 50% for grades 0, I, II,
and III, resp.) (data not shown).
3.5. Impact of IR on Treatment Outcome (Subgroup Analysis).
HOMA was estimated in a small subgroup of 78 patients,
all noncirrhotic. This subgroup was representative of the
total, as no statistical signiﬁcant diﬀerences in patient and
viral baseline characteristics were recorded. Compared to
the total patient sample, this subgroup of patients pre-
sented higher prevalence of hepatic steatosis (59.1% versus
31.7%).
Baseline patient metabolic status, included measure-
ments of fasting glucose levels (median 96mg/dL, 25th–75th
interquartile range (IqR): 90–102), fasting insulin (median
9mIU/mL, IqR: 5.0–14.5), c-peptide (median 2.3ng/mL,
IqR: 1.6–3.0), total cholesterol (median 172mg/dL, IqR:
140–202), and serum triglycerides (median 83mg/dL, IqR:
69–108).MedianHOMAwas2.2(IqR:1.1–4.1).Halfofthese
patients (51.1%) were found insulin resistant by deﬁnition
(HOMA ≥2).
IR was associated with older age (χ2, P = 0.041), BMI
(Student’s t-test, P<0.001) and presence of hepatic steatosis
(χ2, P<0.001). HOMA correlated with BMI after loga-
rithmic transformation (Pearson’s correlation, r = 0.544,
P = 0.006) and with presence of hepatic steatosis (Mann-
Whitney test, P<0.001). Finally, prevalence of insulin
resistance was greater in non-responders than responders
(63.6% versus 38.5%), but this diﬀerence did not reach the
level of statistical signiﬁcance (Figure 2).
Table 4: Variable associations with presence of hepatic steatosis.
No steatosis
(n = 241)
Hepatic steatosis
(n = 113) P values
Gender (males%) 136 (56.4) 59 (52.2) 0.457
Age ≥ 40 years (n%) 132 (55.0) 71 (65.1) 0.075
IVDU (n%) 80 (33.3) 31 (27.4) 0.265
Alcohol abuse (n%) 20 (8.5) 21 (20.0) 0.003
BMI (kg/m2)2 3 .6 ±3.52 3 .6 ±4.8 0.988
Overweight (n%) 18 (34.6) 30 (37.5) 0.736
Genotype distribution 0.721
Genotype 1 117 (49.4) 46 (43.0)
Genotype 2 15 (6.3) 8 (7.5)
Genotype 3 76 (32.1) 37 (34.6)
Genotype 4 29 (12.2) 16 (15.0)
High viral load (n%) 27 (32.9) 40 (54.1) 0.008
Abnormal ALT (n%) 231 (97.9) 98 (92.5) 0.015
Abnormal AST (n%) 202 (89.0) 74 (79.6) 0.026
Severe inﬂammation
(n%) 5 (2.2) 12 (12.0) <0.001
Advanced ﬁbrosis (n%) 22 (9.2) 34 (30.1) <0.001
Cirrhosis (n%) 9 (3.8) 12 (10.6) 0.011
SVR (n%) 185 (76.8) 64 (56.6) <0.001
3.6. Impact of HCV Genotype on Host Metabolic Proﬁle. Only
genotype 1 (n = 164) and genotype 3 (n = 113) HCV
patients were selected for further statistical analysis, in order
to examine possible diﬀerences in their metabolic proﬁle.
Genotype 3 patients were mostly younger (P<0.001),
former IVDUs (P<0.001), and responded better to antiviral
treatment (86.7% versus 67.7%, P<0.001). Diﬀerences
in hepatic steatosis were also recorded (χ2 test, df = 3,
P = 0.032), while BMI was similar (23.6 ± 4.8v e r s u s
23.1±3.4kg/m 2,S t u d e n t ’ st-test, P = 0.561), and diﬀerences
in HOMA did not reach the level of statistical signiﬁcance
(median HOMA 2.7 (IqR: 1.5–4.2) in genotype 1 versus
1.8 (IqR: 0.8–3.1) in genotype 3, and Mann-Whitney test,
P = 0.315).
Further statistical analysis, as shown in Table 5, revealed
the following.
(i) Genotype 3 HCV patients were mostly younger,
former IVDUs, but this did not seem to be related to
the presence of steatosis.
(ii) Gender and BMI did not diﬀer between genotypes 1
and3norinﬂuencedthepresenceofhepaticsteatosis.
(iii) Alcohol abuse was strongly associated with presence
of hepatic steatosis independently of genotype.
(iv) HOMA was higher in patients with hepatic steatosis
independently of genotype.
(v) High viral load inﬂuenced the presence of hepatic
steatosis only in genotype 3 patients.6 Gastroenterology Research and Practice
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Figure 2: Prevalence of host metabolic factors in responders and
nonresponders.
(vi) Severe necro-inﬂammatory activity was associated
with hepatic steatosis in genotype 1 patients but not
in genotype 3 patients.
(vii) Strong correlations of hepatic steatosis and ﬁbrosis
were recorded in both genotypes.
4. Discussion
4.1. Treatment Outcome and Impact of Host Metabolic Factors.
In this cohort of patients, SVR rates ranged between 40
and 86.7% according to genotype, clearly higher than those
previously reported in large clinical trials [1–3]. This could
partly be explained by the fact that this was a retrospective
study with strict deﬁned exclusion criteria and no intention
to treat analysis. Comparison between diﬀerent genotypes
revealed that young age was the strongest determinant for
the high SVR rate encountered in genotype 3 patients. On
the other hand, genotype 4 presented the worst prognosis.
Systematic review of the literature showed that data on the
eﬃcacy of current antiviral therapy of genotype 4 CHC
infection are limited and contradictory [35]; SVR rates of
60% reported in endemic areas [35, 36] are at least 2-times
higher than those encountered in Southern Europe [37, 38].
In Greece, genotype 4 accounts for approximately 15% of
all HCV infections and is generally considered as “diﬃcult
to treat” in everyday clinical practice [39]. Certainly, this
contradiction has to be addressed in future studies.
The results of this study indicate that histological evi-
dence of hepatic steatosis in pretreatment liver biopsy is an
independent prognostic factor for nonresponse to current
antiviral therapy. BMI and HOMA were also associated
with treatment outcome. However, their impact could not
have been established in the multivariate logistic regression,
probably because of the strong associations between hepatic
steatosis, BMI, and IR.
Several reports in the literature have already documented
the importance of host metabolic factors on treatment
response, deﬁning either steatosis [22, 23]o rI R[ 28, 29]
as independent factors. Systematic review of the literature
reveals that there is not a certain metabolic factor to
determine treatment response, but a total metabolic burden
of the host that interferes with the therapeutic process and
decreases the possibility of achieving SVR.
4.2.DeterminantsofHepaticSteatosis. Theoverallprevalence
of hepatic steatosis in our study was 31.8%, distributed in
20.8%, 9%, and 2.5% for grades I, II, and III, respectively,
similar to those reported previously [6, 23, 40]. The reported
prevalence of hepatic steatosis in CHC patients ranges
between 34.8 and 81.2% [7]. This wide range itself indicates
that several independent factors may inﬂuence presence of
steatosis.
One major determinant of steatosis, supported by most
authors, is genotype 3 [6, 22, 40–43], which directly leads
to hepatocyte steatogenesis. In this setting, association of
steatosis with HCV RNA mirrors this direct cytopathic eﬀect
of HCV, and also explains why genotype 3 CHC presents
withmoreseveregradesofhepaticsteatosis [38].Correlation
of fatty liver and increased BMI has been found in some
studies [6, 23, 24, 41–43], even though this correlation
has been suggested to be limited to nongenotype 3 CHC
patients [7, 43, 44]. The association of hepatic steatosis
and advanced ﬁbrosis, supported by the “two hit” theory,
is not a constant ﬁnding [6, 22, 36–38]. In our study,
associations of hepatic steatosis with ﬁbrosis were recorded
in both genotypes, while with necro-inﬂammatory activity
were recorded only in genotype 1 patients, which implies
possible diﬀerent interactions concerning mechanisms of
hepaticsteatogenesis.Itisalsostillnotclearwhethersteatosis
correlates with age and aminotrasferase activity or whether
these variables act as confounding factors.
Finally, it has already been well documented that both
alcohol and HCV induce liver steatosis by acting syner-
gistically in the hepatocyte. Toxic eﬀects of ethanol and
its metabolites include mainly alterations on mitochondrial
lipid oxidation and proinﬂammatory cytokine production.
Using the relatively small cutoﬀ limit of 120g alcohol per
week in our study, we found that past alcohol intake wasGastroenterology Research and Practice 7
Table 5: Diﬀerences of genotypes 1 and 3 in determinants of hepatic steatosis.
Genotype 1 Genotype 3
P values∗
No steatosis
n = 117
Steatosis
n = 46 P values No steatosis
n = 76
Steatosis
n = 37 P values
Gender (males%) 65 (55.6) 21 (45.7) NS 42 (55.3) 24 (64.9) NS NS
Age ≥ 40 years (n%) 75 (64.1) 35 (77.8) NS 26 (34.7) 15 (41.7) NS 0.001
IVDU (n%) 31 (26.5) 9 (19.6) NS 40 (53.3) 19 (51.4) NS 0.005
Alcohol abuse (n%) 7 (6.0) 8 (18.2) 0.030 7 (9.7) 10 (27.8) 0.024 NS
BMI (kg/m2)2 4 .0 ±4.22 3 .5 ±5.3N S2 2 .9 ±3.22 3 .3 ±3.5N S N S
HOMA 1.6 (1.4–1.6) 4.0 (3.5–4.3) 0.024 0.8 (0.7–1.1) 2.8 (2.4–4.1) 0.016 NS
High viral load (n%) 10 (27.0) 13 (41.9) NS 13 (40.6) 19 (73.1) 0.018 0.031
Severe inﬂammation (n%) 2 (1.8) 8 (20.0) >0.001 1 (1.4) 2 (6.3) 0.231 NS
Advanced ﬁbrosis (n%) 11 (9.4) 12 (26.1) 0.011 5 (6.8) 12 (32.4) 0.001 NS
SVR (n%) 87 (74.4) 23 (50.0) 0.005 70 (92.1) 28 (75.7) 0.035 0.023
∗Comparison between genotype 1 patients with steatosis (n = 46) and genotype 3 patients with steatosis (n = 37) (columns 3, 6, and 8).
associated with presence of hepatic steatosis irrespective
of genotype. However, it is still debated in the literature
whetherpastalcoholconsumption,andinwhatextent,could
inﬂuence viral steatogenic mechanisms.
4.3. Genotype-Related Diﬀerences. Results derived from the
comparison between genotype 1 and genotype 3 HCV
patients conﬁrmed the steatogenic and cytopathic eﬀect of
genotype 3, as prevalence of hepatic steatosis was found
higher in the latter. Viral load was also found to be associated
with hepatic steatosis only in genotype 3 patients, similar to
other reports [6, 41].
Furthermore, in a similar way with the study of Fartoux
and colleagues [44], hepatic steatosis was found to be associ-
atedwithpastalcoholintake,insulinresistance,andpresence
of advanced ﬁbrosis. Inﬂammation, although mostly mild,
as expected, and not diﬀerent between two genotypes, was
foundtobeassociatedwithhepaticsteatosisonlyingenotype
1 patients. This could possibly be an indication that viral-
related steatosis encountered in genotype 3 results less from
noninﬂammatory processes in liver parenchyma.
Another interesting diﬀerence with the study of Fartoux
was the fact that neither BMI nor HOMA was found to be
diﬀerent between two genotypes, indicating that metabolic
factors are present even in genotype 3 HCV patients, where
steatosis was believed to be exclusively virus related.
5. Conclusion
The close association of HCV and hepatic steatosis has
already been well documented by several investigators.
Recent data also suggest that CHC has to be considered a
metabolic disease further to a viral infection. Our study,
despite the limitations by its retrospective nature, indicates
that metabolic factors may impact treatment outcome of
standard antiviral therapy, and that hepatic steatosis in
genotype 3 has to be considered as the result of complex
interplay between metabolic and viral factors and not
exclusively virus related as previously reported. This “mixed
type” of hepatic steatosis is expected to be increasingly
recognized in the future. In this setting, and in the era of new
emerging antivirals, a metabolic approach could be helpful,
especially for those patients who do not beneﬁt from current
antiviral treatment.
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